منابع مشابه
"How then shall we live?".
This address did not originate in my neocortex, but in a deeper region of my brain, the one responsible for signaling a sense of warning. The sense I have is that a subtle, distinct change is occurring around me that is not quite right. This sense eventually grew into the perception that society, in general, and medicine, in particular, are devaluing the ideals of service and sacrifice. I did n...
متن کاملHow I Treat How we treat lower-risk myelodysplastic syndromes
Myelodysplastic syndromes (MDSs) are clonal stem cell disorders characterized by ineffective hematopoiesis leading to blood cytopenias, and by a high incidence of progression to acute myeloid leukemia (AML). The pathophysiology of MDS is a multistep process involving genetic changes detectable by conventional cytogenetic techniques or smaller anomalies detectable only by more sophisticated meth...
متن کاملHow I Treat How we treat higher-risk myelodysplastic syndromes
s. 2012;120(21):1696. 73. Itzykson R, Kosmider O, Cluzeau T, et al;Groupe Francophone des Myelodysplasies(GFM). Impact of TET2 mutations on responserate to azacitidine in myelodysplastic syndromesand low blast count acute myeloid leukemias.Leukemia. 2011;25(7):1147-1152. 74. Sekeres MA, List AF, Cuthbertson D, et al.Phase I combination trial of lenalidomide andazacit...
متن کاملHow we treat Waldenström's macroglobulinemia.
Waldenström's macroglobulinemia (WM) is a lymphoplasmacytic lymphoma which produces monoclonal immunoglobulin M (IgM). Over the last decade, new treatment modalites have been developed for the management of this disorder. Our objective is to provide treatment recommendations for WM. A review of published reports was facilitated by a MEDLINE computer search and by a manual search of Index Medicu...
متن کاملHow we treat Richter syndrome.
Richter syndrome (RS) is defined as the transformation of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). RS occurs in approximately 2% to 10% of CLL patients during the course of their disease, with a transformation rate of 0.5% to 1% per year. A combination of germline genetic characteristics, clinical features (eg, advanced...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 1866
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.1.286.655